The Technical Analyst
Select Language :
Freeline Therapeutics [FRLN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Freeline Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Freeline Therapeutics is listed at the  Exchange

0.15% $6.49

America/New_York / 16 feb 2024 @ 15:37


Freeline Therapeutics: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 28.28 mill
EPS: -11.40
P/E: -0.569
Earnings Date: Feb 28, 2024
SharesOutstanding: 4.36 mill
Avg Daily Volume: 0.0281 mill
RATING 2024-02-16
B-
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/a
Gr.Profitn/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.569 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.10x
Company: PE -0.569 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 6.42 - 6.54

( +/- 0.99%)
ATR Model: 14 days

Forecast: 01:40 - $7.07

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $6.49 (0.15% )
Volume 0.0053 mill
Avg. Vol. 0.0281 mill
% of Avg. Vol 19.01 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Freeline Therapeutics Holdings

Last 12 Months

Last 12 months chart data with high, low, open and close for Freeline Therapeutics Holdings

RSI

Intraday RSI14 chart for Freeline Therapeutics Holdings

Last 10 Buy & Sell Signals For FRLN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Freeline Therapeutics Holdings

FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Last 10 Buy Signals

Date Signal @
USDTUSDMar 28 - 19:17$1.000
KUBUSDMar 28 - 19:082.69
FISUSDMar 28 - 19:030.952
PROPCUSDMar 28 - 18:585.09
XCADUSDMar 28 - 18:571.490
INDEXUSDMar 28 - 18:565.95
FUMOUSDMar 28 - 18:5410 001
ALPHUSDMar 28 - 18:542.71
HNTUSDMar 28 - 18:47$6.19
WBTUSDMar 28 - 18:438.37

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.